ALK oncogenic activation mechanisms were characterized in four conventional spindle-cell inflammatory myofibroblastic tumours (IMT) and five atypical IMT, each of which had ALK genomic perturbations. Constitutively activated ALK oncoproteins were purified by ALK immunoprecipitation and electrophoresis, and were characterized by mass spectrometry. The four conventional IMT had TPM3/4-ALK fusions (two cases) or DCTN1-ALK fusions (two cases), whereas two atypical spindle-cell IMT had TFG-ALK and TPM3-ALK fusion in one case each, and three epithelioid inflammatory myofibroblastic sarcomas had RANBP2-ALK fusions in two cases, and a novel RRBP1-ALK fusion in one case. The epithelioid inflammatory myofibroblastic sarcoma with RRBP1-ALK fusion had cytoplasmic ALK expression with perinuclear accentuation, different from the nuclear membranous ALK localization in epithelioid inflammatory myofibroblastic sarcomas with RANBP2-ALK fusions. Evaluation of three additional uncharacterized epithelioid inflammatory myofibroblastic sarcomas with ALK cytoplasmic/perinuclear-accentuation expression demonstrated RRBP1-ALK fusion in two cases. These studies show that atypical spindle-cell IMT can utilize the same ALK fusion mechanisms described previously in conventional IMT, whereas in clinically aggressive epithelioid inflammatory myofibroblastic sarcoma we identify a novel recurrent ALK oncogenic mechanism, resulting from fusion with the RRBP1 gene.
Introduction
Most inflammatory myofibroblastic tumours (IMTs) arise in abdominopelvic locations and are composed of spindled neoplastic myofibroblasts admixed with reactive lymphoplasmacytic cells. Whereas conventional spindle-cell IMTs are neoplasms of intermediate biological potential that recur or metastasize infrequently [1] [2] [3] , the epithelioid variant of IMT, known as epithelioid inflammatory myofibroblastic sarcoma (EIMS) [4, 5] , is clinically aggressive and has a dismal prognosis. Conventional spindle-cellRRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma 317 [6, 7] . By contrast, EIMSs typically have RAN-binding protein 2 (RANBP2)-ALK fusion oncoproteins with a distinctive nuclear membranous localization, owing to the roles of RANBP2 in the nuclear pore complex [4, 5] . Nonetheless, some EIMSs have cytoplasmic ALK expression, implicating ALK fusion partners other than RANBP2. In this study, we used proteomic strategies to characterize novel ALK fusion oncoproteins in atypical IMTs. These analyses focused on the EIMS variant, but we also analysed atypical spindled IMT with nuclear atypia or ganglion-like tumour cells, which is an IMT variant in which ALK perturbations have not been evaluated previously.
Materials and methods

Tumour samples
IMT specimens and other ALK-positive tumours were identified from the pathology archives of the investigators' hospitals, and the histology and immunostains for each IMT were reviewed by two soft tissue pathologists (J.L.H. and J.C.L.). The study was approved by the research ethics committees of each institution.
Immunoprecipitation and immunoblotting
Immunoprecipitations and immunoblotting were performed with methods described previously [8] .
Immunoprecipitations were performed with 1 mg of IMT protein lysate and 2 μg of monoclonal anti-ALK antibody (Dako, Glostrup, Denmark; clone ALK1). Immunoblotting was performed with antibodies against ALK (Invitrogen -Thermo Fisher Scientific, Carlsbad, CA, USA; 51-3900), phosphotyrosine (Santa Cruz Biotechnologies, Santa Cruz, CA, USA; pY99, sc-7020), dynactin subunit 1 (DCTN1) (Santa Cruz Biotechnologies), and ribosome-binding protein 1 (RRBP1) (Novus Biologicals, Littleton, CO, USA).
Analysis of ALK fusion proteins by mass spectrometry
Aberrant-sized ALK proteins were identified with phosphotyrosine and ALK immunoblot stains, and then excised from gels stained with Coomassie blue and subjected to in-gel trypsin digestion, extraction, reverse-phase high-performance liquid chromatography (HPLC) elution, electrospray ionization, and analysis by ion-trap mass spectrometry [8] . Peptide fragmentation patterns were matched against protein databases by the use of SEQUEST algorithms.
Reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing
Total RNA was extracted from IMTs with TRIZOL LS reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed with the iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). Primer sequences for RT-PCR and Sanger sequencing are shown in supplementary material, Table S1 .
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on 4-μm paraffin sections as described previously [9] . Flanking sequences upstream of RRBP1 and downstream of ALK were detected with bacterial artificial chromosomes RP11-588 F17 and RP11-373D23, respectively.
Results
Clinicopathological features
Of the 15 IMTs analysed in this study (Table 1) , snap-frozen materials were available for nine, which could therefore be used in the proteomic screens. Formalin-fixed paraffin-embedded (FFPE) materials were available for all IMTs, and all cases were known to have ALK rearrangements, by previously performed ALK break-apart FISH. Histological features (Table 1; supplementary material, Figure S1 ) demonstrated three IMT subtypes: (1) conventional spindle-cell low-grade IMT with lymphoplasmacytic infiltrate and ALK cytoplasmic staining (n = 4); (2) atypical spindle-cell hypercellular IMT with conspicuous ganglion-like tumour cells and nuclear atypia, along with lymphoplasmacytic infiltrate and cytoplasmic ALK expression (n = 2); and (3) EIMS (n = 9) with large round vesicular nuclei and prominent nucleoli, neutrophil-predominant inflammatory cells in a fibromyxoid stroma, and either ALK nuclear membrane staining (n = 4) or ALK cytoplasmic staining (n = 5; four with perinuclear accentuation).
Characterization of ALK fusion proteins
Each of the nine snap-frozen IMTs expressed tyrosine-phosphorylated ALK proteins of aberrant sizes ( Figure 1 ). Two conventional IMTs (C1 and C2) and one atypical spindle-cell IMT (A5) expressed ALK proteins consistent in size with the TPM3/TPM4-ALK oncoproteins reported previously by our group [10] . TPM3/TPM4-ALK fusions were confirmed (Table 1; Figure 2 ) in each of these cases by RT-PCR. The remaining IMT expressed phosphorylated ALK proteins of 75-95 kDa (A2), 140-180 kDa (A4), 185 kDa (A1 and A3), and 240 kDa (C3 and C4). ALK proteins of each size (A1, A2, A4, and C3) were purified from Coomassie blue-stained gels, and characterized by mass spectrometry, revealing RANBP2-ALK, TRK-fused gene protein (TFG)-ALK, DCTN1-ALK, and RRBP1-ALK in IMTs A1, A2, C3 and A4, respectively ( Figure 2 ; supplementary material, Figure  S2 ). Each of the ALK fusion partners contributed a coiled-coil domain that was retained in the ALK fusion protein ( Figure 2 ). The protein sequences were consistent with fusions of RANBP2 exon 18, TFG exon 5 and DCTN1 exon 26 to ALK exon 20. RANBP2-ALK, TFG-ALK and DCTN1-ALK are previously reported ALK fusions in IMT [5, 11, 12] , whereas RRBP1-ALK is a novel ALK fusion. RRBP1-ALK incorporates not only RRBP1 coiled-coil domains but also an RRBP1 endoplasmic reticulum transmembrane domain and a ribosome receptor domain ( Figure 3 ).
Validation of mass spectrometry results
The N-terminal regions of DCTN1 (in IMTs C3 and C4) and RRBP1 (in IMT A4) co-precipitated and co-localized with the ALK C-terminus in these tumours, corroborating the DCTN1-ALK and novel RRBP1-ALK fusions (supplementary material, Figure S3 ). RT-PCR demonstrated RANBP2-ALK, TFG-ALK, DCTN1-ALK and RRBP1-ALK fusion transcripts, as predicted by mass spectrometry ( Figure 2B ). Likewise, TPM3-ALK or TPM4-ALK fusions were corroborated by RT-PCR in cases A5, C1, and C2 ( Figure 2B ; Table 1 ). The RRBP1-ALK fusion resulted from use of an alternative splice acceptor site within RRBP1 intron 20 (agACCCCGG … ), such that the RRBP1-ALK open reading frame resulted from fusion of RRBP1 exon 20 to a 33-nucleotide sequence from RRBP1 intron 20, which was in turn fused to ALK exon 20 ( Figure 2B ).
RRBP1-ALK is a recurrent oncogenic mechanism in clinically aggressive EIMS
FFPE materials from six additional unselected EIMSs were studied (cases different from the above-mentioned IMT frozen-specimen series). Two of these (A6 and A7; Table 1 ) had nuclear membrane ALK expression consistent with RANBP2-ALK. RT-PCR demonstrated RANBP2-ALK in A6 and was unsuccessful in A7. The other four cases (A8, A9, A10, and A11; Table 1 ) had cytoplasmic ALK expression, with perinuclear accentuation in A8, A9, and A10 (Figure 4) . Interphase FISH demonstrated RRBP1-ALK in 34 of 51 cells (67%) from A8, and in 59 of 100 cells (59%) from A9 ( Figure 4 ). RRBP1-ALK cases A8 and A9, like A4, had fulminant clinical progression: patient A4 died of progressive EIMS 2 months after diagnosis, and patients A8 and A9 had EIMS recurrence with disseminated intra-abdominal metastases within 10 months after resection of the primary tumour (Table 1) .
RRBP1-ALK is not found in ALK-positive cancers other than EIMS
To evaluate the specificity of RRBP1-ALK, we evaluated ALK immunohistochemical expression patterns in 100 ALK-positive neoplasms, including 20 lung adenocarcinomas, 25 anaplastic large-cell lymphomas, 25 epithelioid fibrous histiocytomas, and 30 conventional IMTs. None of these showed the distinctive pattern of perinuclear accentuation of cytoplasmic staining found in RRBP1-ALK EIMSs (data not shown).
Discussion
We characterized tyrosine-phosphorylated ALK oncoproteins in clinical IMT specimens (Table 1) , leading to the discovery of RRBP1-ALK as a novel and recurrent ALK fusion gene in clinically aggressive EIMS. RRBP1-ALK has not been described previously in IMTs, but in this study we demonstrated RRBP1-ALK in three of four EIMSs in which ALK expression was cytoplasmic with perinuclear accentuation (Figure 4) . The studies focused on atypical IMTs, evaluating ALK fusion oncogenes in EIMSs and in spindle-cell IMTs with nuclear atypia and a ganglion-like component. Whereas all six IMTs with RANBP2-ALK or RRBP1-ALK in this series were clinically aggressive EIMSs, the TPM3-ALK and TFG-ALK fusions found in one atypical spindled IMT each have been reported previously in conventional IMTs, and are therefore not specific for atypical IMTs. Therefore, we hypothesize that the various ALK fusions in conventional IMTs can sustain tumours that occasionally develop atypical histological features, although they remain fundamentally lower-grade and spindled entities. Acquired atypia in these IMTs might result from additional genetic aberrations, as suggested by previous studies [2, 13, 14] . By contrast, EIMSs with RANBP2-ALK or RRBP1-ALK appear to constitute a morphologically and clinically distinct subgroup of IMTs that are of higher grade from the outset, rather than a transformation from conventional IMTs. Similarly to what has been found for RANBP2-ALK fusions, which have been demonstrated only in EIMSs and haematological neoplasms, our studies suggest that RRBP1-ALK fusions are restricted mechanisms among human cancers. We did not find the characteristic immunohistochemical pattern of RRBP1-ALK expression in 100 ALK-positive lung adenocarcinomas, anaplastic large-cell lymphomas, sequencing data, did not find RRBP1-ALK in 6893 human cancers from the TCGA programme; these cases included 102 sarcomas, and included tumours in the differential diagnosis of EIMS, e.g. 33 dedifferentiated liposarcomas [15] . Similarly, Yoshihara et al did not find RRBP1-ALK in a partially overlapping set of 7717 human cancers, using a different fusion caller, the Pipeline for RNA sequencing Data Analysis (http://54.84.12.177/PanCanFusV2/) [16] , and neither did Giacomini et al find RRBP1-ALK in 974 human cancers studied with DNA breakpoint or RNA breakpoint analyses [17] .
RRBP1 is a coiled-coil protein that functions in interactions between ribosomes and the endoplasmic reticulum, and also in microtubule binding [18] . These biological roles probably account for the distinctive cytoplasmic and perinuclear ALK localization in EIMSs with RRBP1-ALK. RRBP1 overexpression has been implicated as a marker of poor prognosis in breast and colorectal cancer [19, 20] , but the IMT studies reported here provide the first demonstration of an RRBP1 oncogenic mechanism. RRBP1-ALK retained the N-terminal RRBP1 coiled-coil domain (Figures 2  and 3) , and hence is one of various ALK fusion oncoproteins, such as TPM3-ALK [21] , in which a coiled-coil fusion partner dictates ALK oncogenic activation.
Notably, RRBP1-ALK and RANBP2-ALK are the only recurrent oncogenic mechanisms identified to date in EIMSs. It is intriguing that RRBP1-ALK and RANBP2-ALK have not been found in conventional low-grade spindled IMTs. These findings indicate that RRBP1-ALK and RANBP2-ALK are biologically relevant only in the very high-grade epithelioid subtype of IMT, or indeed that these particular ALK fusions are directly responsible for the high proliferative status and distinctive epithelioid morphology of EIMSs. Because RRBP1 and RANBP2 both interact with the cell microtubule apparatus through binding to kinesin family member 5B and other kinesins [22, 23] , it will be worthwhile to determine whether RRBP1 and RANBP2 have shared biological mechanisms in their respective ALK fusions, unique among the other various ALK fusion oncoproteins in IMT. Although mechanistic evaluations of RRBP1-ALK have not yet been performed, it is notable that forced RRBP1 overexpression has been shown to alter cell shape, possibly through microtubule interactions [18] . These observations suggest that RRBP1-ALK oncoproteins contribute to epithelioid morphology by dysregulating the usual interactions between RRBP1 and microtubules. However, additional studies are needed to evaluate these hypotheses.
This study has limitations. First, although our studies and database reviews do not demonstrate evidence of RRBP1-ALK in common cancers or in IMT histological mimics, we cannot exclude the possibility that other uncommon cancer subtypes might have this novel oncogenic mechanism. Second, although the clinicopathological findings reported herein reveal an aggressive clinical course for each of three EIMSs with RRBP1-ALK, additional studies are needed to determine whether this is invariably the case. Third, additional studies are needed to determine whether EIMSs with RRBP1-ALK respond favourably to ALK inhibitor therapies, as do EIMSs with RANBP2-ALK [24] .
In conclusion, proteomic evaluations of ALK oncoproteins identified RRBP1-ALK as a novel and recurrent oncogenic mechanism in clinically aggressive EIMSs. These methods were efficient in demonstrating ALK fusion identities and oncogenic functions (aberrant size and constitutive tyrosine phosphorylation) directly in the clinical specimens, rather than in costly laboratory models, which are often only approximations of the clinical entities. The novel RRBP1-ALK fusion led to cytoplasmic and perinuclear ALK expression, in contrast to the typical nuclear membranous ALK expression pattern in EIMSs harbouring RANBP2-ALK.
